Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2401388rdf:typepubmed:Citationlld:pubmed
pubmed-article:2401388lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:2401388lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:2401388lifeskim:mentionsumls-concept:C0441800lld:lifeskim
pubmed-article:2401388lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:2401388lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:2401388lifeskim:mentionsumls-concept:C1998793lld:lifeskim
pubmed-article:2401388pubmed:dateCreated1990-10-19lld:pubmed
pubmed-article:2401388pubmed:abstractTextA strategy for the purification of murine IgG monoclonal antibodies (MAbs) is described. It consists of a combination of protein A affinity chromatography and ion exchange chromatography. The method was used for the purification of two MAbs, WT31 and MN12. After in vitro cultivation in the presence of foetal bovine serum, the medium components were efficiently removed from the MAbs, yielding clinical grade products. Automated purification under aseptic conditions was effectuated by employing a computer-controlled four-column system.lld:pubmed
pubmed-article:2401388pubmed:languageenglld:pubmed
pubmed-article:2401388pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2401388pubmed:citationSubsetIMlld:pubmed
pubmed-article:2401388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2401388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2401388pubmed:statusMEDLINElld:pubmed
pubmed-article:2401388pubmed:issn0301-5149lld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:BeuveryE CEClld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:CrommelinD...lld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:JiskootWWlld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:GebbinckJ WJWlld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:2401388pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:2401388pubmed:issnTypePrintlld:pubmed
pubmed-article:2401388pubmed:volume71lld:pubmed
pubmed-article:2401388pubmed:ownerNLMlld:pubmed
pubmed-article:2401388pubmed:authorsCompleteYlld:pubmed
pubmed-article:2401388pubmed:pagination73-8lld:pubmed
pubmed-article:2401388pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:meshHeadingpubmed-meshheading:2401388-...lld:pubmed
pubmed-article:2401388pubmed:year1990lld:pubmed
pubmed-article:2401388pubmed:articleTitleA purification strategy for the production of clinical grade monoclonal antibodies.lld:pubmed
pubmed-article:2401388pubmed:affiliationDepartment of Pharmaceutics, Faculty of Pharmacy, University of Utrecht, The Netherlands.lld:pubmed
pubmed-article:2401388pubmed:publicationTypeJournal Articlelld:pubmed